Leukemia treatment "Beijing program" breaks through the world's problems
Leukemia treatment "Beijing program" breaks through the world's problems November 28, 2016 Source: Xinhua News Agency As a malignant blood disease, leukemia mortality ranks first in children with malignant disease mortality and sixth in adult malignant disease mortality. The most effective way to treat the disease is to perform a hematopoietic stem cell transplant, or bone marrow transplant. However, bone marrow transplantation must be performed with 100% homogeneity of human leukocyte antigen (HLA), otherwise severe rejection will occur. The original program of the Chinese medical team successfully broke through the worldwide problem of leukemia bone marrow transplant donor deficiency, becoming the first choice for more than half of the world's haploid bone marrow transplant patients. At the 7th Asian Cell Therapy Organization Annual Meeting, which was recently closed in Beijing, experts from various countries confirmed the contribution of the program to the world. As a malignant blood disease, leukemia mortality ranks first in children with malignant disease mortality and sixth in adult malignant disease mortality. The most effective way to treat the disease is to perform a hematopoietic stem cell transplant, or bone marrow transplant. However, bone marrow transplantation must be performed with 100% homogeneity of human leukocyte antigen (HLA), otherwise severe rejection will occur. But even the siblings, the probability of total coincidence is only 25%, and the population without blood relationship is only one in 100,000. Since the end of the last century, countries around the world have carried out clinical research on haploid bone marrow transplantation technology. The so-called haploid transplantation refers to a technique in which a patient can receive a transplant even when the bone marrow stem cells are half-matched. However, when this technology was first introduced, the patients who received the transplant had a large rejection response, and the survival rate after transplantation was only 20%. Since 1996, the team led by Huang Xiaojun, director of the Institute of Hematology, Peking University, has begun to explore the mechanism of granulocyte colony-stimulating factor inhibiting cell rejection in humans. On this basis, Chinese original haploid bone marrow has gradually formed. Transplant technology system. Nowadays, this "habitat donor" haploid transplantation technology has matured, and its postoperative success rate is 70%, which is equivalent to the success rate of the full-match bone marrow transplantation, while the success rate of similar transplantation technologies in Britain and the United States is only 40. %. As of the end of 2015, more than 5,000 domestic leukemia patients have been cured through this program. At present, the program is used as a clinical routine in France, Italy, Israel, Japan, South Korea and other countries, covering more than 50% of the world's similar transplants. In 2016, the program was officially named the “Beijing Program†for leukemia treatment by the World Bone Marrow Transplant Association, and it is recommended as a reliable global transplant solution for the lack of a fully compatible donor. The program has also been written into the international authoritative textbook for bone marrow transplantation and has been cited by the relevant guidelines of the Bone Marrow Transplant Association in the United States and the United Kingdom. "20% of leukemia patients in Japan cannot find a fully compatible donor. After treatment with the Chinese regimen, the prognosis is good," said Xia Yang, vice president of the World Cell Therapy Organization. Forbey, the former chairman of the European Society of Hematology, said that the Chinese program has set new standards for leukemia bone marrow transplantation technology, benefiting tens of millions of leukemia patients worldwide.
Shikonin is a kind of organic substance, which is insoluble in water, soluble in ethanol, organic solvent and vegetable oil. It is easy to dissolve in alkali water and precipitate when meeting acid. It can be used in the treatment of acute icteric or non icteric hepatitis, chronic hepatitis and verruca plana. It is also effective for cirrhosis (ascites) and verruca vulgaris. It has anti-cancer, anti-inflammatory, antibacterial and other effects. It is used in the treatment of acute and chronic hepatitis and cirrhosis (ascites). The Department of Dermatology and Hepatology is used for the treatment of verruca plana and psoriasis, local application for the treatment of burns and promoting wound healing. Eye drops are effective in the treatment of herpes simplex keratitis.
Product Name: Shikonin
Other Name : Shikonin Powder
Specification: 10%/30%/ 98%
Appearance: Dark Red Purple Powder
Form: Powder
Storage: Store in cool and dry places, keep away from strong light.
Why choose us?
Product Recommended
Berberine Hydrochloride,Shikimic Acid Powder,Kaempferol Powder,Quercetin Powder Xi'an Tian Guangyuan Biotech Co., Ltd. , https://www.tgybiotech.com
1.Shikonin extract shikonin with the function of anti-tumor effects;
2.Shikonin extract shikonin acts the main role of the cardiovascular system;
3.Shikonin extract shikonin with acne and anti-inflammatory cosmetic effects;
4.Shikonin extract shikonin is mainly used for hepatitis, dermatitis and baby, women vaginitis, cervicitis, and other drugs
5.Shikonin has antimicrobial, anticancer and anti-inflammatory effect.
6.Shikonin is used in treating chronic hepatitis, oxyhepatitis and cirrhosis.
7.Shikonin is used in treating verruca plana and psoriasis.
8.Shikonin is also known to have wound healing, antitumor, and antithrombotic properties.
9.Shikonin works as colorant in cosmetic and food products.
